Stool vs. Serum Hepatitis B Virus DNA in Patients with Chronic Hepatitis B

JiShun, Zheng; Chen, Meng-meng; Yang, Haifei; Zhou, Xiangtian; Liu, Yanyan; Li, Jiabin

doi:10.12659/msm.896243

Cited by 3 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A growing body of literature suggests a connection between gut microbiota dysbiosis and disease progression in CHB patients. [20][21][22][23][24][25][26][27] Additionally, emerging data reveals that directed treatment of dysbiosis may have potential therapeutic value in liver disease and CHB management. 28-3 0 Therefore, it is necessary to clarify our understanding of the pathophysiology of gut microbiota, understand their relationship with liver injury in CHB, identify the data gap, and wholly assess the latest microbiota-targeted therapies in CHB patients.…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, further development of new treatment methods are critical for the global eradication of HBV. A growing body of literature suggests a connection between gut microbiota dysbiosis and disease progression in CHB patients 20–27 . Additionally, emerging data reveals that directed treatment of dysbiosis may have potential therapeutic value in liver disease and CHB management 28–30 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The role of gut microbiota in hepatitis B disease progression and treatment

Chen

Huang

Pan

2021

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Current therapeutic interventions can only suppress hepatitis B virus (HBV) replication or reduce complications without a cure. Therefore, further development of new treatment methods is critical for the global eradication of HBV. Accumulating evidence suggests that the liver and gut share an interconnected relationship referred to as the 'Gut-Liver Axis', where exchanges happen bi-directionally. The gut itself is the host to a unique microbiota profile which has metabolic, immunological, neurological and nutritional functions. Gut microbiota is not only constantly intersecting with the liver but also associated with hepatic injury when dysbiosis occurs. In recent years, there has been increased interest in gut microbiota and its implications on liver disease treatment. Progress has been made in understanding the complex relationship between chronic hepatitis B (CHB) and gut microbiota. New investigative techniques such as colony-free sequencing enabled new perspectives into this field.Mouse models and human studies revealed that HBV infection is associated with significant alteration of gut microbiota, which differ depending on the stage of CHB disease progression. Different mechanisms of the hepatic injury from gut microbiota dysbiosis have also been proposed based on findings of increased intestinal permeability to toxins, disruption of normal bacterial metabolism, and colonization of the gut by oral microbiota. New treatment methods targeting gut microbiota in CHB, such as probiotics and faecal microbiota transplant, have also gained promising results in recent years. The current review recapitulated the most recent investigations into the relationship between gut microbiota and CHB to provide research directions towards the new therapeutic target of CHB.

show abstract